{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:00:07Z","timestamp":1778252407583,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T00:00:00Z","timestamp":1471219200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00125-016-4071-8","type":"journal-article","created":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T12:31:13Z","timestamp":1471264273000},"page":"2426-2434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice"],"prefix":"10.1007","volume":"59","author":[{"given":"Hiroyuki","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iseki","family":"Takamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaito","family":"Iwayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumpei","family":"Tokuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Moroi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Sugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Nakaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritaka","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahito","family":"Jomori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,15]]},"reference":[{"key":"4071_CR1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/diab.37.6.667","volume":"37","author":"RA DeFronzo","year":"1988","unstructured":"DeFronzo RA (1988) Lilly lecture, 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667\u2013687","journal-title":"Diabetes"},{"key":"4071_CR2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s00125-009-1313-z","volume":"52","author":"EJ Barrett","year":"2009","unstructured":"Barrett EJ, Eggleston EM, Inyard AC et al (2009) The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia 52:752\u2013764","journal-title":"Diabetologia"},{"key":"4071_CR3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cmet.2011.01.018","volume":"13","author":"T Kubota","year":"2011","unstructured":"Kubota T, Kubota N, Kumagai H et al (2011) Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 13:294\u2013307","journal-title":"Cell Metab"},{"key":"4071_CR4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","volume":"18","author":"M Nauck","year":"2015","unstructured":"Nauck M (2015) Incretin therapies: highlighting common features and differences in the modes of action of GLP-1 receptor agonists and DPP-4 inhibitors. Diabetes Obes Metab 18:203\u2013216","journal-title":"Diabetes Obes Metab"},{"key":"4071_CR5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","volume":"32","author":"M Nauck","year":"2009","unstructured":"Nauck M, Frid A, Hermansen K et al (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care 32:84\u201390","journal-title":"Diabetes Care"},{"key":"4071_CR6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"Buse JB, Rosenstock J, Sesti G et al (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39\u201347","journal-title":"Lancet"},{"key":"4071_CR7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s13300-014-0087-6","volume":"5","author":"V Divino","year":"2014","unstructured":"Divino V, DeKoven M, Hallinan S et al (2014) Glucagon-like peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries. Diabetes Ther 5:499\u2013520","journal-title":"Diabetes Ther"},{"key":"4071_CR8","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jdiacomp.2015.07.020","volume":"29","author":"R Usui","year":"2015","unstructured":"Usui R, Yabe D, Kuwata H, Murotani K, Kurose T, Seino Y (2015) Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: association of remaining beta cell function and achievement of HbA1c target one year after initiation. J Diabet Complications 29:1203\u20131210","journal-title":"J Diabet Complications"},{"key":"4071_CR9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.diabres.2014.01.019","volume":"104","author":"G D\u0131az-Soto","year":"2014","unstructured":"D\u0131az-Soto G, de Luis DA, Conde-Vicente R, Izaola-Jauregui O, Ramos C, Romero E (2014) Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study. Diabetes Res Clin Pract 104:92\u201396","journal-title":"Diabetes Res Clin Pract"},{"key":"4071_CR10","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.2337\/dc13-0354","volume":"36","author":"SH Kim","year":"2013","unstructured":"Kim SH, Abbasi F, Lamendola C et al (2013) Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care 36:3276\u20133282","journal-title":"Diabetes Care"},{"key":"4071_CR11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","volume":"373","author":"A Garber","year":"2009","unstructured":"Garber A, Henry R, Ratner R et al (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52\u00a0week, phase 3, double-blind, parallel treatment trial. Lancet 373:473\u2013481","journal-title":"Lancet"},{"key":"4071_CR12","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.2337\/db13-1597","volume":"63","author":"W Chai","year":"2014","unstructured":"Chai W, Zhang X, Barrett EJ, Liu Z (2014) Glucagon-like peptide 1 recruits muscle microvasculature and improves insulin's metabolic action in the presence of insulin resistance. Diabetes 63:2788\u20132799","journal-title":"Diabetes"},{"key":"4071_CR13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mce.2010.04.022","volume":"325","author":"O Erdogdu","year":"2010","unstructured":"Erdogdu O, Nathanson D, Sjoholm A, Nystrom T, Zhang Q (2010) Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K\/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 325:26\u201335","journal-title":"Mol Cell Endocrinol"},{"key":"4071_CR14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","volume":"214","author":"R Mentlein","year":"1993","unstructured":"Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829\u2013835","journal-title":"Eur J Biochem"},{"key":"4071_CR15","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","volume":"44","author":"CF Deacon","year":"1995","unstructured":"Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ (1995) Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126\u20131131","journal-title":"Diabetes"},{"key":"4071_CR16","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1210\/jc.2006-1009","volume":"91","author":"GA Herman","year":"2006","unstructured":"Herman GA, Bergman A, Stevens C et al (2006) Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91:4612\u20134619","journal-title":"J Clin Endocrinol Metab"},{"key":"4071_CR17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s13300-012-0010-y","volume":"3","author":"T Rauch","year":"2012","unstructured":"Rauch T, Graefe-Mody U, Deacon CF et al (2012) Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Ther 3:10","journal-title":"Diabetes Ther"},{"key":"4071_CR18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2125.2011.04109.x","volume":"73","author":"CB Landersdorfer","year":"2012","unstructured":"Landersdorfer CB, He YL, Jusko WJ (2012) Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. Br J Clin Pharmacol 73:373\u2013390","journal-title":"Br J Clin Pharmacol"},{"key":"4071_CR19","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1463-1326.2012.01662.x","volume":"14","author":"T Eto","year":"2012","unstructured":"Eto T, Inoue S, Kadowaki T (2012) Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 14:1040\u20131046","journal-title":"Diabetes Obes Metab"},{"key":"4071_CR20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000351678","volume":"123","author":"Y Nakamura","year":"2013","unstructured":"Nakamura Y, Inagaki M, Shimizu T et al (2013) Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study. Nephron Clin Pract 123:46\u201351","journal-title":"Nephron Clin Pract"},{"key":"4071_CR21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1507\/endocrj.EJ14-0544","volume":"62","author":"HK Yang","year":"2015","unstructured":"Yang HK, Min KW, Park SW et al (2015) A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-na\u00efve patients with type 2 diabetes. Endocr J 62:449\u2013462","journal-title":"Endocr J"},{"key":"4071_CR22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/713609354","volume":"40","author":"AM Lambeir","year":"2003","unstructured":"Lambeir AM, Durinx C, Scharp\u00e9 S, De Meester I (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40:209\u2013294","journal-title":"Crit Rev Clin Lab Sci"},{"key":"4071_CR23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/0-387-32824-6_3","volume":"575","author":"X Chen","year":"2006","unstructured":"Chen X (2006) Biochemical properties of recombinant prolyl dipeptidases DPP-IV and DPP8. Adv Exp Med Biol 575:27\u201332","journal-title":"Adv Exp Med Biol"},{"key":"4071_CR24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0167-0115(93)90435-B","volume":"49","author":"R Mentlein","year":"1993","unstructured":"Mentlein R, Dahms P, Grandt D, Kr\u00fcger R (1993) Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 49:133\u2013144","journal-title":"Regul Pept"},{"key":"4071_CR25","doi-asserted-by":"crossref","first-page":"7221","DOI":"10.1016\/j.bmc.2011.09.043","volume":"19","author":"N Kato","year":"2011","unstructured":"Kato N, Oka M, Murase T et al (2011) Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino) -2-methylpropyl]-2-methyl pyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg Med Chem 19:7221\u20137227","journal-title":"Bioorg Med Chem"},{"key":"4071_CR26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s13318-013-0119-z","volume":"38","author":"S Furuta","year":"2013","unstructured":"Furuta S, Tamura M, Hirooka H, Mizuno Y, Miyoshi M, Furuta Y (2013) Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs. Eur J Drug Metab Pharmacokinet 38:87\u201396","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"4071_CR27","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2337\/diabetes.47.5.764","volume":"47","author":"CF Deacon","year":"1998","unstructured":"Deacon CF, Hughes TE, Holst JJ (1998) Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47:764\u2013769","journal-title":"Diabetes"},{"key":"4071_CR28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cmet.2008.05.007","volume":"8","author":"N Kubota","year":"2008","unstructured":"Kubota N, Kubota T, Itoh S et al (2008) Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab 8:49\u201364","journal-title":"Cell Metab"},{"key":"4071_CR29","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.2337\/diabetes.53.6.1418","volume":"53","author":"MA Vincent","year":"2004","unstructured":"Vincent MA, Clerk LH, Lindner JR et al (2004) Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes 53:1418\u20131423","journal-title":"Diabetes"},{"key":"4071_CR30","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2337\/diab.42.10.1469","volume":"42","author":"PA Jansson","year":"1993","unstructured":"Jansson PA, Fowelin JP, von Schenck HP, Smith UP, Lonnroth PN (1993) Measurement by microdialysis of the insulin concentration in subcutaneous interstitial fluid. Importance of the endothelial barrier for insulin. Diabetes 42:1469\u20131473","journal-title":"Diabetes"},{"key":"4071_CR31","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.2337\/diabetes.51.9.2742","volume":"51","author":"M Sjostrand","year":"2002","unstructured":"Sjostrand M, Gudbjornsdottir S, Holmang A, Lonn L, Strindberg L, Lonnroth P (2002) Delayed transcapillary transport of insulin to muscle interstitial fluid in obese subjects. Diabetes 51:2742\u20132748","journal-title":"Diabetes"},{"key":"4071_CR32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2337\/diabetes.50.3.573","volume":"50","author":"T Ogihara","year":"2001","unstructured":"Ogihara T, Asano T, Ando K et al (2001) Insulin resistance with enhanced insulin signaling in high-salt diet-fed rats. Diabetes 50:573\u2013583","journal-title":"Diabetes"},{"key":"4071_CR33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2337\/diabetes.52.2.365","volume":"52","author":"DD Leon De","year":"2003","unstructured":"De Leon DD, Deng S, Madani R, Ahima RS, Drucker DJ, Stoffers DA (2003) Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 52:365\u2013371","journal-title":"Diabetes"},{"key":"4071_CR34","first-page":"847","volume":"40","author":"Y Sunami","year":"2012","unstructured":"Sunami Y, Sesoko S, Kaku K (2012) Pharmacokinetics and pharmacodynamics of single and multiple doses of anagliptin, a novel inhibitor of dipeptidyl peptidase-4. Jpn Pharmacol Ther 40:847\u2013858 [article in Japanese]","journal-title":"Jpn Pharmacol Ther"},{"key":"4071_CR35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1210\/en.2012-1937","volume":"154","author":"N Panjwani","year":"2013","unstructured":"Panjwani N, Mulvihill EE, Longuet C et al (2013) GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-\/-) mice. Endocrinology 154:127\u2013139","journal-title":"Endocrinology"},{"key":"4071_CR36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jacc.2011.07.053","volume":"59","author":"J Matsubara","year":"2012","unstructured":"Matsubara J, Sugiyama S, Sugamura K et al (2012) A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 59:265\u2013276","journal-title":"J Am Coll Cardiol"},{"key":"4071_CR37","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2337\/db11-1073","volume":"61","author":"W Chai","year":"2012","unstructured":"Chai W, Dong Z, Wang N et al (2012) Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 61:888\u2013896","journal-title":"Diabetes"},{"key":"4071_CR38","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/hr.2014.53","volume":"37","author":"H Nakagami","year":"2014","unstructured":"Nakagami H, Pang Z, Shimosato T et al (2014) The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR\/NDmcr-cp rat model of metabolic syndrome. Hypertens Res 37:629\u2013635","journal-title":"Hypertens Res"},{"key":"4071_CR39","doi-asserted-by":"crossref","first-page":"E222","DOI":"10.1152\/ajpendo.00473.2012","volume":"304","author":"Z Dong","year":"2013","unstructured":"Dong Z, Chai W, Wang W et al (2013) Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment. Am J Physiol Endocrinol Metab 304:E222\u2013E228","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4071_CR40","first-page":"532","volume":"65","author":"M Kusunoki","year":"2015","unstructured":"Kusunoki M, Sato D, Nakamura T et al (2015) DPP-4 inhibitor teneligliptin improves insulin resistance and serum lipid profile in Japanese patients with type 2 diabetes. Drug Res 65:532\u2013534","journal-title":"Drug Res"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-016-4071-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-016-4071-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-016-4071-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T10:58:25Z","timestamp":1499770705000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-016-4071-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,15]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["4071"],"URL":"https:\/\/doi.org\/10.1007\/s00125-016-4071-8","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,15]]}}}